Buy Sun Pharma; target of Rs 1200: Motilal Oswal
Motilal Oswal is bullish on Sun Pharma recommended buy rating on the stock with a target price of Rs 1200 in its research report dated January 19, 2023.21-01-2023
21-01-2023
How acquiring Concert Pharmaceuticals can boost Sun Pharma's speciality pipeline
The acquisition, Sun Pharma said, is aimed at accessing Concert's experimental drugDeuruxolitinib--a potential treatment of Alopecia Areata, a skin disease causing partial or complete loss of hair on the scalp and body.20-01-2023
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
Additional Information - Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Agreement to Acquire Concert Pharmaceuticals Inc.19-01-2023
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Acquisition
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Agreement to Acquire Concert Pharmaceuticals, Inc.19-01-2023
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Sun Pharma to announce third quarter results on January 31, 2023.17-01-2023
Sun Pharma Q3 PAT may dip 4% YoY to Rs 19,767 cr: Nirmal Bang
Net Sales are expected to increase by 14 percent Y-o-Y (up 2.7 percent Q-o-Q) to Rs 1,12,458 crore, according to Nirmal Bang.17-01-2023
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Clarification Sought From The Company
Please find attached letter for clarification sought from the Company.17-01-2023
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39 3 ) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 201516-01-2023
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Corporate Action-Board to consider Dividend
This is to inform that the meeting of the Board of Directors of Sun Pharmaceutical Industries Limited is scheduled to be held on Tuesday, January 31, 2023, inter alia, - 1. To consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2022 2. To consider and approve declaration of Interim Dividend for the financial year 2022-23 Record date for Interim Dividend The interim dividend, if declared, shall be paid to the equity shareholders of the Company whose names appear on the Register of Members as on February 8, 2023 which is the Record Date fixed for this purpose.16-01-2023
SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Board Meeting Intimation for Consideration Of Financial Results And Interim Dividend
SUN PHARMACEUTICAL INDUSTRIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2023 ,inter alia, to consider and approve 1. Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2022 2. Declaration of Interim Dividend for the financial year 2022-2316-01-2023